Skip to main content
  • nl
  • fr
  • en
Other official information and services: www.belgium.be
Logo of the Belgian Federal Authorities
Return to the FAMHP homepage
Your medicine and health products
  • About the FAMHP
  • Jobs
  • Publications
  • Press
  • Contact
  • Complaints
  • Webportal
  • Home
  • Human medicines
  • Veterinary medicines
    • Medicines
    • Particular products
      • Raw materials
        • Approved laboratories
        • Authorisations
        • Authorised raw materials
          • List of the authorised raw materials
          • List of the not marketed raw materials
          • List of the removed raw materials
        • Fees
        • Scope
      • Specially reglemented substances
      • Grey area
    • Health products
  • Information for the public
  • Notification of adverse reactions or incidents
  • Home
  • Veterinary medicines
  • Particular products
  • Raw materials
  • Authorised raw materials
  • List of the not marketed raw materials
  • Medicines
    • Medicines
  • Particular products
    • Raw materials
    • Specially reglemented substances
    • Grey area
  • Health products
    • Medical devices and their accessories

List of the not marketed raw materials

La liste des matières premières "hors marché" sera publiée dès que cette disposition sera appliquée aux matières premières.

L'état actuel de la législation ne le permet pas encore.

Last updated on 15/01/2009

Notification of adverse reactions or incidents

PIL and SPC
of a medicine

(PIL: patient information leaflet SPC: summary of product characteristics)

Search

News

12/02/2019
New verification system against falsified medicines in each link in the distribution chain
12/02/2019
Practical recommendations for the new verification systems against falsified medications
30/01/2019
Flash VIG-news: LYNPARZA® (olaparib): risk of medication errors with new pharmaceutical form
29/01/2019
Notifications about anti-tampering device (ATD) or devices to prevent tampering on packaging of existing drugs that do not fall under the Falsified Medicines Directive
All news

© 2016 - FAMHP

  • Site map
  • Disclaimer
  • Complaints
  • Contact